Local drug makers mulls remuneration over API manufacturer

With the new DMF (drug master file) system to take effect next year, local drug manufacturers are considering paying any royalty-like money to DMF-endorsed API (active pharmaceutical ingredient) manufacturers, to get their permission beforehand.

“We are willingness to pay to the DMF holder if the quality of DMF-accredited APIs is deemed acceptable,” a company official said.

Under the new ...